Board Member
Chemomab Therapeutics Ltd. (CMMB)Chairman
Chemomab Therapeutics Ltd. (CMMB)Equibles does not estimate personal net worth.
Get an email with a short summary when Chemomab Therapeutics Ltd. publishes a filing, an earnings call transcript or a press release.
Get CMMB alertsDale Pfost is recorded as CEO, Board Member and Chairman at Chemomab Therapeutics Ltd. (CMMB). The newest filing on record that lists Dale Pfost as CEO and Board Member at Chemomab Therapeutics Ltd. (CMMB) is dated April 28, 2022. Dale Pfost has spoken on 4 earnings calls across 1 company, most recently for Chemomab Therapeutics Ltd. on May 11, 2023. Chemomab Therapeutics Ltd. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Chemomab Therapeutics Ltd. includes Adi Mor (CEO and Board Member), Dr. Adi Mor (CEO), Dr. Dale Pfost (CEO) and 7 others.
“Welcome to the Chemomab conference call covering updates through the first quarter of 2023. I am pleased to report that we have continued to make good progress on multiple fronts since our last investor call.”
“I am pleased to report that we have continued to make good progress on multiple fronts since our last call. Today, I will cover the following three advances we achieved during the third quarter.”
“I am pleased to report we have continued to make good progress on multiple fronts since our last call. These include first, advancing our clinical programs for CM-101, our first in-class monoclonal antibody that neutralizes CCL-24, a novel disease target at the confluence of fibrosis and inflammation.”
“It's just been two months since our last conference call and I'm pleased to report that we have been making good progress in refining and implementing the revisions to the CM-101 clinical program that we outlined in March.”
Start not stated–present
Last confirmed April 28, 2022
Start not stated–present
Last confirmed April 28, 2022
Biotechnology · Healthcare
CEO, Board Member, Chairman
